LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that it has surpassed 1,000 early-stage platform subscribers as it continues development of mobile healthcare applications for the Apple App Store and Google Play Store. The company is focused on telehealth infrastructure and healthcare analytics for emerging markets, particularly Latin America.
The mobile applications under development are designed to support a range of healthcare functions, including telehealth, patient engagement, provider coordination, emergency response, and AI-assisted healthcare. These tools are part of LataMed's broader strategy to build a scalable digital healthcare ecosystem for underserved regions where access to healthcare coordination and digital tools is limited.
According to the company, the applications are being prepared for submission to both app stores after further development, internal testing, and regulatory reviews. Management emphasized that the technologies are still in active development and have not been fully commercialized. No timeline has been provided for public release or availability.
The milestone of surpassing 1,000 early subscribers is seen by management as an indicator of early interest and engagement with the LataMed AI platform. The company believes that continued user onboarding will provide valuable feedback as it refines its platform and expands functionality.
Dr. Kevin Rodan Levy, CEO of LataMed AI Corp., stated: "We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives."
The company's broader technology initiatives focus on scalable healthcare infrastructure solutions for developing markets, where access to healthcare coordination, telehealth services, and digital tools may be fragmented or unavailable. LataMed AI's platform aims to support remote patient engagement, provider coordination, healthcare analytics, and emergency response integration.
LataMed AI Corp. is a development-stage company and faces risks typical of early-stage ventures, including the need for financing, regulatory approvals, and successful commercialization. The company's securities trade on the OTC Markets under the symbol LMED and are considered high risk.
For more information, visit the company's website at https://latamed.ai or review its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
